| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c85c9ec978c2b7936e68b2d418773e1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9b0a6530cc301f263710d2086061a16d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3a59b5587796d7ea65f750d71eeefb74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84d9adaa7e7ce01ce8020f5c721aba10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2010-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fb3eae01103219468d8b567edac77ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d51512e432cfaf6506730991cafe36df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3325551c63c3eda2e25b6ced2f30e62 |
| publicationDate |
2010-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010147899-A1 |
| titleOfInvention |
Stable nanoparticulate drug suspension |
| abstract |
A liquid pharmaceutical composition comprises an aqueous medium having suspended therein a solid particulate Bcl-2 family protein inhibitory compound such as ABT-263, having a D 90 particle size not greater than about 3 μm; wherein the aqueous medium further comprises at least one pharmaceutically acceptable surfactant and at least one pharmaceutically acceptable basifying agent such as sodium bicarbonate in amounts that are effective together to inhibit particle size increase. The composition is suitable for oral or parenteral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11389472-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11491225-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11744853-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11730756-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019055880-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11357792-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11285159-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019083527-A1 |
| priorityDate |
2009-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |